“Cytiva’s solutions provide us with the flexibility and modularity to offer our customers tailored manufacturing. With the addition of Cytiva’s robotic aseptic filling solutions, we are truly an end-to-end, single point of contact CDMO, reducing overall complexity, cost, and time to the product innovators.”
- Mark Bamforth, Executive Chair and CEO, Arranta Bio
Or, extend your facilities with a prefabricated KUBio™ box. This turn-key solution can be on your site in as little as 10 months for efficient manufacturing of mRNA therapeutics and vaccines.
mRNA therapeutics manufacturing starts with DNA plasmid design and production. Plasmids are produced in bacterial cultures, then harvested and purified.
mRNA purification removes enzymes, remaining nucleotides, plasmid DNA, and defective mRNA. New emerging technologies like Fibro chromatography, currently available for mAb purification, are in development for molecules such as DNA plasmids and mRNA.
Lipid nanoparticles (LNPs) are a key technology for making mRNA vaccines and other genetic medicines. The purified mRNA therapeutic is formulated in LNPs as a drug delivery vehicle. Core chromatography can be used to further remove impurities.
Closed robotic workcells for aseptic filling of mRNA vaccines and drug products reduce risk and improve agility. Advance multiple candidates, including personalized vaccines.
